Viewing Study NCT00343551


Ignite Creation Date: 2025-12-24 @ 11:54 PM
Ignite Modification Date: 2025-12-25 @ 9:50 PM
Study NCT ID: NCT00343551
Status: COMPLETED
Last Update Posted: 2017-02-23
First Post: 2006-06-22
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
Sponsor: Novartis
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module